The Chemours Company (CC) 株式分析

企業概要

The Chemours Company is a specialized manufacturer that provides performance chemicals to diverse markets including North America, the Asia Pacific region, Europe, the Middle East, Africa, and Latin America. The firm operates within the Basic Materials sector, specifically targeting the Specialty Chemicals industry, which focuses on producing high-value additives and materials for various industrial applications. As of the latest data, the company maintains a market capitalization of $3.28B and generates annual revenue of $5.81B while employing a workforce of 5,700 individuals. These valuation and revenue figures indicate that the enterprise holds a mid-to-large-scale position within the global specialty chemicals landscape, supported by its operations across three primary segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials.

財務健全性

The company reported a total revenue of $5.81B over the trailing twelve months, yet recorded a net income loss of $386,000,000, while generating an EBITDA of $637.00M. The substantial disparity between the positive EBITDA of $637.00M and the negative net income of $386,000,000 reveals a significant cost structure burden, likely driven by non-operating expenses such as interest costs on substantial debt or one-time charges that are deducted after EBITDA but before arriving at net income. Regarding cash generation, the free cash flow stands at $21.50M, which suggests limited financial flexibility to fund major capital expenditures or aggressive debt repayment without external financing. The balance sheet shows a cash position of $670.00M against total debt of $4.39B, resulting in a debt-to-equity ratio of 1750.60, which characterizes the balance sheet as highly leveraged rather than conservative. Liquidity is assessed via a current ratio of 1.78, indicating that the company possesses sufficient current assets to cover short-term obligations more than 1.5 times over. However, the return metrics present a challenging picture with a return on equity of -93.8% and a return on assets of 2.5%, revealing that management effectiveness has been severely impacted by the net loss, as negative ROE reflects that shareholder equity has declined significantly relative to profits.

バリュエーション評価

Valuation multiples show a trailing P/E ratio of N/A due to the current net losses, whereas the forward P/E is listed at 9.80, implying that the market expects earnings to recover or stabilize in the coming period to support a multiple. The price-to-book ratio sits at 13.09, indicating that the market prices the company's equity at a significant premium relative to its tangible book value, likely due to the scarcity of its specific chemical assets or future growth expectations. Alternative valuation metrics include a price-to-sales ratio of 0.56 and an EV/EBITDA of 10.99, which suggest that despite the earnings deficit, the company is trading at a valuation comparable to peers based on sales efficiency and enterprise value relative to operating cash earnings. Price action over the last year has ranged between a low of $9.13 and a high of $22.43, meaning the current stock price trades within this historical volatility band, reflecting the uncertainty surrounding its earnings turnaround. The beta of 1.40 indicates that the stock exhibits price volatility that is 40% higher than the broader market, suggesting it is more sensitive to market fluctuations than the average equity in the index.

Growth & Income

Revenue growth for the trailing twelve months was -2.1%, while earnings growth is N/A due to the reported net loss, indicating that top-line contraction is currently outpacing any potential earnings recovery or that earnings are entirely driven by non-recurring factors. The company pays a dividend with a yield of 1.6%, but the payout ratio stands at 555.6%, which is not sustainable given the negative net income, as the company is paying out more in dividends than it earns in profit. This high payout ratio in conjunction with negative earnings implies that the dividends are being funded through cash reserves or debt rather than operational profitability, creating a potential risk for future dividend cuts if cash flow does not improve. Overall, the growth and income profile is characterized by revenue contraction, unsustainable dividend coverage relative to earnings, and a high-beta stock price that reflects the significant risks associated with the company's current financial leverage and operational challenges.